Novel Niacin Compositions for Reduction of Amyloid Beta Peptide 42 (AB42) Production and for Treatment of Alzheimer's Disease
申请人:Saxena Uday
公开号:US20130338199A1
公开(公告)日:2013-12-19
The present invention discloses (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol hybrid with cocrystal former like eugenol and oxalic acid (3) novel pharmaceutical compositions comprising a combination of niacin and one or more small molecule/potentiating agent like eugenol, curcumin, cinnamic acid, meclofenamic acid, and their use in the treatment of a disorder or a disease caused by excess production of amyloid beta peptide-42 (Aβ42), its deposition, accumulation, and plaque formation including Alzheimer's Disease, dementia and mild cognitive impairment as well as other neurodegenerative diseases such as Parkinson's Disease, Huntington's disease, multiple sclerosis, amytrophic lateral sclerosis and ischemic stroke.
本发明公开了(1)烟酸与m-甲氧基-p-羟基苯基化合物如丁香酚、香草醛、狗毒素、阿魏酸、异阿魏酸和丁香酚环氧化物的酚酯杂化物,以及(2)上述杂化物的共晶体,特别是烟酸-丁香酚杂化物与丁香酚和草酸等共晶体形成剂的共晶体,以及(3)新型药物组合物,包括烟酸和一种或多种小分子/增效剂,如丁香酚、姜黄素、肉桂酸、美洛昔康酸,用于治疗由淀粉样β肽42(Aβ42)过度产生、沉积、蓄积和斑块形成引起的疾病或症状,包括阿尔茨海默病、痴呆和轻度认知障碍,以及其他神经退行性疾病,如帕金森病、亨廷顿病、多发性硬化症、肌萎缩侧索硬化和缺血性中风。